Trial Profile
A Phase 1, Non-Randomized, Open-Label, Single Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 13 Jul 2017 Results published in the Journal of Clinical Pharmacology
- 27 Oct 2014 Status changed from recruiting to completed,as reported by ClinicalTrials.gov
- 07 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Oct 2014, as reported by ClinicalTrials.gov